Evidence map›Paper›PMID 36328489›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus

Ismaheel O Lawal, Ashesh B Jani, Omotayo A Adediran, Subir Goyal, Olayinka A Abiodun-Ojo, Vishal R Dhere, Charles V Marcus, Shreyas S Joshi, Viraj A Master, Pretesh R Patel and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 2 countries.

Ismaheel O LawalDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia; ilawal@emory.edu.
Ashesh B JaniDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Omotayo A AdediranDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Subir GoyalBiostatics Shared Resource, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Olayinka A Abiodun-OjoDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Vishal R DhereDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Charles V MarcusDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Shreyas S JoshiDepartment of Urology, Emory University, Atlanta, Georgia; and.
Viraj A MasterDepartment of Urology, Emory University, Atlanta, Georgia; and.
Pretesh R PatelDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Mark GoodmanDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Joseph W SheltonDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Omer KucukDepartment of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Bruce HershatterDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
Bridget FielderDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Raghuveer K HalkarDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
David M SchusterDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Emory University · US

Funding

Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy RadiotherapyR01CA169188 · NCI · EMORY UNIVERSITY · PI JANI, ASHESH, SCHUSTER, DAVID MICHAEL · 2012 to 2016
$2.1M
NCI NIH HHS R01 CA169188
6 · The paper itself

Abstract

The EMPIRE-1 (Emory Molecular Prostate Imaging for Radiotherapy Enhancement 1) trial reported a survival advantage in recurrent prostate cancer salvage radiotherapy (SRT) guided by

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsAndrogen AntagonistsCarboxylic AcidsCyclobutanesHumansMaleNeoplasm Recurrence, LocalProstatectomyProstate-Specific AntigenAndrogen AntagonistsCarboxylic AcidsCyclobutanesfluciclovine F-18Prostate-Specific Antigen18F-fluciclovine PET/CTadverse pathologyEMPIRE-1 trialprostate cancerprostate-specific antigensalvage radiotherapy

Identifiers

PMID36328489
PMCPMC10071787
OpenAlexW4308076483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.